Last updated: July 30, 2025
Introduction
China Patent CN101723143, titled "Preparation method of a drug-containing self-assembling nanoparticle," pertains to pharmaceutical nanotechnology, specifically focusing on drug delivery systems utilizing self-assembling nanostructures. As part of the rapidly evolving nanomedicine domain, this patent's scope, claims, and positioning within the patent landscape are critical for stakeholders involved in drug development, licensing, and intellectual property (IP) strategy.
Scope of Patent CN101723143
Technological Field:
This patent addresses formulations in nanomedicine, especially methods for preparing drug-loaded self-assembling nanoparticles. These nanocarriers are designed to improve therapeutic efficacy by enhancing solubility, targeting, and controlled release.
Core Innovation:
The patent encompasses a method to produce drug-containing nanoparticles via self-assembly, involving specific components such as carriers, drugs, and optional stabilizers, under defined process conditions. It emphasizes the innovative assembling process that results in nanoparticles with desirable characteristics like uniformity, stability, and biocompatibility.
Application Scope:
The technology applies broadly across pharmaceuticals requiring nanoparticle delivery systems, including anticancer, anti-inflammatory, and antiviral drugs. It is adaptable to both hydrophilic and hydrophobic drugs, making its scope relevant for a diverse range of therapeutic agents.
Legal Scope and Breadth:
The patent claims are crafted to safeguard the particular formulation process and characteristic features of the nanoparticles. While the claims are specific, they are sufficiently broad to cover various drug combinations and nanoparticle formulations utilizing similar self-assembly techniques, as long as they meet the outlined process parameters.
Claims Analysis
1. Claim Structure Overview:
The claims of CN101723143 predominantly concern the process of preparing drug-containing self-assembling nanoparticles. They specify key steps such as mixing components, controlling parameters like temperature and pH, and the resulting nanoparticle properties.
2. Independent Claims:
The main independent claim broadly claims a method for preparing drug-loaded nanoparticles characterized by self-assembly, involving specific steps such as:
- Dissolving drug and carrier materials,
- Inducing self-assembly through controlled conditions,
- Isolating the nanoparticles for pharmaceutical use.
The claim emphasizes the novelty of the process rather than the final product alone, providing strategic leverage for future patentability and enforcement.
3. Dependent Claims:
These specify particular features, such as:
- Types of drugs (e.g., anticancer agents),
- Specific carrier materials (e.g., phospholipids, copolymers),
- Process parameters (e.g., temperature range, mixing speeds),
- Characteristics of the nanoparticles (e.g., size range, stability).
The dependent claims enhance the scope by covering additional embodiments, thus providing a layered patent protection.
4. Claim Scope and Potential Limitations:
While the claims are detailed, they rely on specific process steps and parameters. This could limit the patent's robustness against design-arounds that modify the process or utilize alternative self-assembly mechanisms. Future patent challenges might target claims for novelty or inventive step if similar methods exist or are disclosed in prior art—particularly in the global nanomedicine field.
Patent Landscape Context
Global Nanoparticle Drug Delivery Patents:
China's nanomedicine patent landscape is dynamic, with significant activity in self-assembling drug delivery platforms. Patents from entities such as Chinese Academy of Sciences, universities (e.g., Fudan University), and biotech companies focus on formulations, manufacturing processes, and targeted delivery innovations.
Related Patents and Prior Art:
Key prior art includes international patents and publications around self-assembling peptide and lipid nanoparticles, such as US patents related to liposomal and micelle-based carriers. Notably, work by researchers like Lee and Kwon (2014, Adv. Drug Deliv. Rev.) established foundations for self-assembly in nanomedicine.
In China, similar patents address various methods of nanoparticle preparation, often with overlapping scope but differing in process specifics. CN101723143’s niche lies in its particular process conditions and formulation strategies, offering a degree of differentiation.
Positioning within the Patent Landscape:
CN101723143 complements existing Chinese patents by focusing on specific process innovations and formulations. Its unique contribution lies in detailed steps controlling nanoparticle characteristics, which can be defensible if supported by experimental data demonstrating improved stability or efficacy.
Potential for Patent Challenges:
Given the generic nature of self-assembly methods, patent validity may face scrutiny based on prior art disclosures. Clear novelty may depend on the specific process parameters or nanoparticle properties claimed. Strategic players may seek examiners' opposition or patent invalidation based on earlier publications or existing patents.
Implications for Stakeholders
-
Pharmaceutical Developers:
This patent offers a method to develop stable, reproducible drug-loaded nanoparticles, advantageous for formulations targeting stability and bioavailability issues.
-
Patent Owners and Licensors:
The scope provides room for licensing or cross-licensing, especially in the Chinese market, given the patent's coverage of a flexible self-assembly process.
-
Legal and IP Strategy:
Companies should monitor similar filings and invent around claims by modifying core process steps or exploring different self-assembly mechanisms. Patent litigators must scrutinize claim language’s breadth to assess enforceability.
Conclusion
China Patent CN101723143 exemplifies a strategically crafted process patent in the expanding field of nanomedicine. Its scope encompasses a versatile method for assembling drug-containing nanoparticles via self-assembly techniques, with claims tailored to balance breadth and specificity. While offering promising protection in China’s growing pharmaceutical IP landscape, the patent's robustness against potential challenges will depend on prior art analysis and ongoing technological developments.
Key Takeaways
-
Innovation Focus:
The patent centers on a specific manufacturing process for self-assembling drug nanoparticles, emphasizing process parameters for uniformity and stability.
-
Scope and Claims:
Claims are process-oriented, covering methods of preparation and nanoparticle features. While broad, they are specific enough to secure meaningful protection, though open to design-around strategies.
-
Patent Landscape Position:
It fills a niche within China's active nanomedicine patent ecosystem, aligning with global trends toward targeted, stable nanoparticle delivery systems.
-
Strategic Considerations:
Developers should analyze their IP landscape for potential overlaps, consider alternative self-assembly techniques, and focus on improving specific claims to strengthen patent position.
-
Legal Outlook:
The patent's enforceability hinges on the novelty of the process parameters; meticulous prior art searches are essential for validation and litigation readiness.
FAQs
1. What distinguishes patent CN101723143 from other nanoparticle drug delivery patents?
It emphasizes a specific self-assembly process with detailed process controls rather than general nanoparticle formulations, providing a targeted protection strategy.
2. How broad is the scope of the claims in this patent?
The claims primarily cover a process for preparing drug-loaded nanoparticles via self-assembly, with specific process parameters and nanoparticle characteristics, offering moderate breadth with room for design-arounds.
3. Can this patent be challenged based on prior art?
Yes. Similar self-assembly methods are documented internationally; a thorough prior art review may reveal overlapping techniques, which could impact validity.
4. How does this patent fit within China's nanomedicine patent landscape?
It complements existing filings focused on nanoparticle manufacturing, addressing a niche in process innovation, thus holding strategic value for domestic patent portfolios.
5. What are the key considerations for companies wanting to develop similar nanoparticle formulations?
They should analyze the specific claims for potential infringement risk, explore alternative assembly methods, and consider filing their own patents to secure freedom to operate.
References
[1] Official Chinese Patent Database. CN101723143. "Preparation method of a drug-containing self-assembling nanoparticle."
[2] Zhang, L., et al. (2014). "Nanoparticle-based drug delivery systems." Adv. Drug Deliv. Rev.
[3] Lee, S., and Kwon, G. S. (2014). "Self-assembled nanostructures in drug delivery." Adv. Drug Deliv. Rev.
